Drug Profile
LY 2775240
Alternative Names: LY-2775240Latest Information Update: 07 Feb 2020
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 07 Feb 2020 No development reported - Phase-I for Psoriasis (In volunteers) in Singapore (PO)
- 08 Nov 2019 Efficacy, safety and pharmacodynamics data from a phase I trial in healthy volunteers presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)
- 17 Nov 2016 Eli Lilly plans a phase I trial in Healthy volunteers in Singapore (PO) (NCT02963779)